BioSpace News Archive

Omega Therapeutics, Inc. (NASDAQ: OMGA) (“Omega”) today announced dosing of the first patient in its Phase 1/2 MYCHELANGELO™ I trial evaluating OTX-2002 for the treatment of relapsed or refractory hepatocellular carcinoma (HCC) and other solid tumor types associated with c-Myc (MYC) oncogene overexpression. OTX-2002.

CytoSorbents Corporation will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the ALTITUDE ® clinical trial evaluating RGX-314 using suprachoroidal delivery for the treatment of patients with diabetic retinopathy at the Retina Society 55th Annual Scientific Meeting taking place in Pasadena, CA , from November 2-5, 2022.

Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022, at 8:30 a.m. ET to discuss third quarter 2022 results and provide a general business update.

ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks.

Deciphera Pharmaceuticals, Inc. today announced that it will report its third quarter 2022 financial results on Thursday, November 3, 2022.

Vizgen today announced the availability of its MERSCOPE™ spatial genomics platform in Asia-Pacific (APAC), Europe, the Middle East and Africa (EMEA).

AVROBIO, Inc today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-02, a first-in-class investigational gene therapy.

OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022.

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.